Revolution Medicines, Inc. SEC filings RVMDW
Revolution Medicines, Inc. has 862 filings in SEC EDGAR's recent list, going back to Dec 21, 2016. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 305B2 | Filing | Apr 15, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 26, 2024 | — |
| CORRESP | Letter to the SEC | Apr 19, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 9, 2024 | — |
| CERT | Filing | Nov 16, 2023 | — |
| 8-A12B | Filing | Nov 15, 2023 | — |
| 425 | Filing | Nov 1, 2023 | — |
| 425 | Filing | Oct 23, 2023 | — |
| EFFECT | Filing | Sep 29, 2023 | — |
| CORRESP | Letter to the SEC | Sep 27, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 20, 2023 | — |
| 425 | Filing | Aug 1, 2023 | — |
| 425 | Filing | Aug 1, 2023 | — |
| 425 | Filing | Aug 1, 2023 | — |
| 425 | Filing | Aug 1, 2023 | — |
| 425 | Filing | Aug 1, 2023 | — |
| 425 | Filing | Aug 1, 2023 | — |
| 425 | Filing | Aug 1, 2023 | — |
| EFFECT | Filing | Feb 3, 2021 | — |
| CORRESP | Letter to the SEC | Feb 1, 2021 | — |
| CORRESP | Letter to the SEC | Feb 1, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 25, 2021 | — |
| DRS | Filing | Jan 21, 2021 | — |
| EFFECT | Filing | Jul 8, 2020 | — |
| CORRESP | Letter to the SEC | Jul 6, 2020 | — |
| CORRESP | Letter to the SEC | Jul 6, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 15, 2020 | — |
| DRS | Filing | Jun 9, 2020 | — |
| EFFECT | Filing | Feb 12, 2020 | — |
| CERT | Filing | Feb 11, 2020 | — |
| CORRESP | Letter to the SEC | Feb 11, 2020 | — |
| CORRESP | Letter to the SEC | Feb 10, 2020 | — |
| CORRESP | Letter to the SEC | Feb 10, 2020 | — |
| 8-A12B | Filing | Feb 6, 2020 | — |
| UPLOAD | Letter from the SEC | Feb 4, 2020 | — |
| CORRESP | Letter to the SEC | Jan 27, 2020 | — |
| CORRESP | Letter to the SEC | Jan 17, 2020 | — |
| UPLOAD | Letter from the SEC | Jan 15, 2020 | — |
| DRSLTR | Filing | Jan 10, 2020 | — |
| DRS/A | Filing | Jan 10, 2020 | — |
| D | Filing | Nov 15, 2019 | — |
| SEC STAFF LETTER | Filing | Nov 12, 2019 | — |
| UPLOAD | Letter from the SEC | Nov 5, 2019 | — |
| SEC STAFF LETTER | Filing | Nov 1, 2019 | — |
| DRS/A | Filing | Oct 31, 2019 | — |
| DRSLTR | Filing | Oct 30, 2019 | — |
| UPLOAD | Letter from the SEC | Oct 16, 2019 | — |
| DRS | Filing | Sep 19, 2019 | — |
| D | Filing | Jul 10, 2018 | — |
| D | Filing | Dec 21, 2016 | — |
Showing 50 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- RVMD (Nasdaq), RVMDW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Redwood City, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1628171
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.